Cetera Investment Advisers
CORT icon

Cetera Investment Advisers’s Corcept Therapeutics CORT Stock Holding History

Cetera Investment Advisers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,895
Closed -$275K – 4839
2025
Q4 		$275K Sell
7,895
-8,199
-51% -$644K ﹤0.01% 3977
2025
Q3 		$1.34M Buy
16,094
+4,965
+45% +$359K ﹤0.01% 2524
2025
Q2 		$817K Buy
11,129
+2,755
+33% +$200K ﹤0.01% 2559
2025
Q1 		$956K Sell
8,374
-13,674
-62% -$832K ﹤0.01% 2290
2024
Q4 		$1.11M Sell
22,048
-5,043
-19% -$264K ﹤0.01% 2099
2024
Q3 		$1.25M Sell
27,091
-11,201
-29% -$398K ﹤0.01% 1957
2024
Q2 		$1.24M Buy
38,292
+2,244
+6% +$61.5K ﹤0.01% 1917
2024
Q1 		$908K Buy
+36,048
New +$852K ﹤0.01% 2154

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Cetera Investment Advisers's CORT Position: Q1 2026 in Review

Cetera Investment Advisers sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 7,895 shares — an estimated $275K sold.

Cetera Investment Advisers first reported a position in CORT in Q1 2024 and held it in 8 quarters. The position peaked at $1.34M in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Cetera Investment Advisers reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cetera Investment Advisers sold 7,895 Corcept Therapeutics shares in Q1 2026, an estimated $275K.
  • Cetera Investment Advisers first reported a position in Corcept Therapeutics in Q1 2024 and held it in 8 quarters.
  • Cetera Investment Advisers's Corcept Therapeutics position peaked at $1.34M in Q3 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.